Needham: 'VIR Strikes an ex-U.S. Deal for the HDV Program; Extends Cash Runway to 4Q27'
Tweet Send to a Friend
Needham analyst Joseph Stringer reiterated an Under Review rating and $14.00 price target on Vir Biotechnology (NASDAQ: VIR).The analyst comments ...
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
